Abstract

The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859, NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis. The invention further includes an in-vitro screening test for the presence of malignant cells in a mammalian tissue; a method of identifying inhibitors of constitutive Stat3 activation, Stat3-DNA binding, Stat5-DNA binding, and/or Stat3 dimerization; and a method of identifying anti-cancer agents

Document Type

Patent

Patent Number

US 7,960,434

Application Serial Number

11/805,217

Issue Date

6-14-2011

Current Assignee

Joint Assignment w/UCFRF: University of South Florida

Assignee at Issuance

Joint Assignment w/UCFRF: University of South Florida

College

Burnett School of Biomedical Sciences

Department

Biomolecular Science Center

Allowance Date

1-6-2011

Filing Date

4-21-2007

Assignee at Filing

Joint Assignment w/UCFRF: University of South Florida

Filing Type

Nonprovisional Application Record

Donated

no

Download Patent

Share

COinS